Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies
MedComm · 2026-05 · 7 (5)
DOI: 10.1002/mco2.70694 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 20.04.2026. Verfasst von Penghui He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery West China Hospital Sichuan University Chengdu China. Die Arbeit nennt 236 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Liver cancer ranks the second leading cause of cancer‐related mortality globally, with a 5‐year overall survival rate of about 14.0%. And hepatocellular carcinoma (HCC) constitutes about 80% of it. Given that HCC often remains asymptomatic in its early stages, the diagnosis of the majority of patients occurs at the intermediate or advanced stages, leading to the missed opportunity for surgical resection. Furthermore, the incidence of recurrence after surgical resection for early‐stage HCC patients can be as high as 70%. In this context, systemic therapies, including targeted therapies and immunotherapies, have emerged as essential therapeutic strategies for advanced HCC. However, resistance and adverse effects limit their efficacy. This review provides an overview of the molecular signaling pathways underlying HCC and potential mechanisms underlying resistance to systemic therapies and discusses potential therapeutic targets within these pathways. We also examine the clinical outcomes of these systemic therapies, highlighting their efficacy, safety profiles, and the challenges of resistance and toxicity. Finally, we outline future directions for HCC treatment, including combination therapies and personalized treatment strategies, which may offer improved treatment outcomes for individuals with HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery West China Hospital Sichuan University Chengdu China.
- Liver Transplant Center Transplant Center West China Hospital Sichuan University Chengdu China.
- Laboratory of Hepatic AI Translation Frontiers Science Center For Disease-Related Molecular Network West China Hospital Sichuan University Chengdu China.
- Intervention Center West China Hospital Sichuan University Chengdu Sichuan China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
He, P., Xie, S., Xie, K., Gao, F., Cai, Y., Huang, Y., Liu, C., Wu, H., Lyu, Y., & Lan, T. (2026). Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies. MedComm, 7(5). https://doi.org/10.1002/mco2.70694
Vancouver
He P, Xie S, Xie K, Gao F, Cai Y, Huang Y, et al. Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies. MedComm. 2026;7(5). doi:10.1002/mco2.70694
BibTeX
@article{He2026,
author = {He, Penghui and Xie, Sinan and Xie, Kunlin and Gao, Fengwei and Cai, Yunshi and Huang, Yan and Liu, Chang and Wu, Hong and Lyu, Yinghao and Lan, Tian},
title = {Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies},
journal = {MedComm},
year = {2026},
volume = {7},
number = {5},
doi = {10.1002/mco2.70694}
}
EUVIMED